Top Markets
#1 Palladium Network Palladium Network +6.67%
#2 Victoria VR Victoria VR +4.08%
#3 Bridged NXPC Bridged NXPC +2.08%
#4 Tornado Cash Tornado Cash +2.06%
#5 龙虾 (Lobster) 龙虾 (Lobster) +1.72%
#6 aixbt by Virtuals aixbt by Virtuals +1.55%
#7 Prom Prom +1.52%
#8 SkyAI SkyAI +1.49%
#9 Wiki Cat Wiki Cat +1.14%
#10 Geodnet Geodnet +0.92%
Coin of the day
Palladium Network Palladium Network
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Clasificación en acciones #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Precio por acción
$0.0009
Última sincronización: 2025-05-27
Capitalización bursátil
$1.15K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Arch Therapeutics, Inc. (ARTH)

Categoría

Healthcare
Ganancias de Arch Therapeutics, Inc. (ARTH)
Ganancias en Jun 2024 TTM: $-12.26M
Secondo gli ultimi rapporti finanziari di Arch Therapeutics, Inc., gli utili attuali della società sono $-12.26M. Nel 2022, la società ha registrato un utile di $-5.28M, un aumento con respecto a agli utili del 2021, che erano di $-6.24M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Arch Therapeutics, Inc. desde 2011 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-12.26M 75.61%
2023 $-6.98M 32.35%
2022 $-5.28M -15.46%
2021 $-6.24M 33.02%
2020 $-4.69M 3.16%
2019 $-4.55M -5.53%
2018 $-4.81M -38.19%
2017 $-7.79M 29.98%
2016 $-5.99M 103.30%
2015 $-2.95M -63.80%
2014 $-8.14M 339.25%
2013 $-1.85M 4,963.48%
2012 $-36.61K 626.84%
2011 $-5.04K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -43,115.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -16,007.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,611.12%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR